Praxis gains after mid-stage data for epilepsy candidate [Seeking Alpha]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Seeking Alpha
100% complete response in a mid-stage trial for patients with photo paroxysmal response, a characteristic of epilepsy. Following an analysis of eight patients in its Phase 2a proof of concept study for PRAX-628, the Massachusetts-based biotech said that 100% and 80% of them indicated a complete response from PPR, also known as photosensitivity after 45mg and 15 mg dosing, respectively. Meanwhile, 20% of those who received 15 mg achieved a partial response, leading to a 12% overall response rate and an 88% complete response rate in the trial. The safety data for PRAX-628 was consistent with results from prior studies. With PPR trials highlighting the anti-seizure efficacy, the company expects to begin an efficacy study for PRAX-628 in H2 2024 targeting patients with focal epilepsy. More on Praxis Precision Medicines Recommended For You More Trending News Recommended For You More Trending News About PRAX Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $117.00 price target on the stock.MarketBeat
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
PRAX
Earnings
- 3/5/24 - Beat
PRAX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 3/29/24 - Form 8-K
- PRAX's page on the SEC website